PNAS publication supports temelimab’s rationale against neurodegeneration in MS
- Research supports neurobiological rationale for evidence of neuroprotection obtained in completed Phase 2b clinical trials
- Protective effects on axonal degeneration and remyelination support potential role of temelimab in treating progressive MS
Geneva, Switzerland, June 26, 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), is delighted to announce that data supporting the mode of action of its lead product (temelimab) in treating MS was published in the Proceedings of the National Academy of Sciences (PNAS). Temelimab is a monoclonal antibody designed to neutralize a pathogenic, viral envelope protein, pHERV-W Env, which plays a causal role in the development of MS.
For more infomation,